Braizon Therapeutics, Inc.
Overview
Braizon Therapeutics has developed Brain Access®, an innovative drug delivery platform technology for treating central nervous system (CNS) diseases by passing through the blood-brain barrier (BBB) which aims to improve drug performance dramatically.
There are many unmet medical needs (UMN) in diseases and disorders of the CNS. Most of medicinal drugs cannot reach the brain, due to a biological barrier, the BBB.
Brain DDS technology is essential for delivering medicines to the brain. Braizon is creating opportunities to conquer CNS diseases with innovative BBB-crossing DDS technology, Brain Access®.
By licensing Brain Access® to pharmaceutical companies and developing its own drug discovery pipeline using Brain Access®, and Braizon aims to improve the outcomes of drug discovery for unmet needs in the CNS dramatically.
Background
Braizon Therapeutics, Inc. was established with the aim of applying and implementing, within the fields of medicine and life science, innovative technology for the delivery of drugs to the brain as the outcome of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
Feature
Brain DDS is essential in drug development for CNS diseases. Braizon Therapeutics' technology(Brain Access®) overcomes major issues on prior brain DDS technology.
Specifically, major advantages of Brain Access® are great improvement on penetration into the brain, safety predictability(the drug to be delivered is encapsulated in micelles without exposing it), and high versatility (Brain Access® could deliver small molecules and ASOs(Antisense Oligo acid) into the brain simply by encapsulating them in micelles).
Even under intensifying competition to develop drug discovery seeds, Brain Access® is expected to dramatically improve the possibility of drug discovery and practical application by pharmaceutical companies.
- Address
- 254,Entrepreneur Lab.,Southern Research Building., The University of Tokyo 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8485
- Established
- 2015年10月30日
